Exploring High-Dose Subcutaneous Delivery Opportunities Through a Gilead-BD Collaboration

Session details:

• How open dialogue and early scientific collaboration enabled phase appropriate de-risking of a high-dose subcutaneous drug delivery strategy
• The value of shared partnership expertise to expand the boundaries of subcutaneous delivery
• How translational science informs combination product development and innovation